Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial
Palleon's HLX79/E-602 achieved remission in all seven high-dose patients by Week 36. Can the small Phase 2 kidney trial support larger studies?
Pharma & Biotech